Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules by Seini Moimoi | Mar 1, 2021 | Portfolio News
LEXEO Therapeutics Announces License Agreement and Consolidation of Pre-clinical Data Package by Seini Moimoi | Mar 1, 2021 | Portfolio News
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update by Seini Moimoi | Feb 25, 2021 | Portfolio News
Eargo Reports Fourth Quarter and Full Year 2020 Financial Results by Seini Moimoi | Feb 25, 2021 | Portfolio News
Axonics® Expands into Stress Urinary Incontinence with the Acquisition of Bulkamid® by Seini Moimoi | Feb 25, 2021 | Portfolio News
